This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

YKP1447

SK Biopharmaceuticals Co., Ltd.

Drug Names(s): YKP1447

Description: YKP1447 is a selective 5-HT2A/5-HT2C/D2/D3 receptor antagonist developed for schizophrenia.

YKP1447 has shown efficacy for both of positive and negative symptoms in appropriate animal models with improved cognitive function. YKP1447 has also shown improved toxicity profile over YKP1358 in the test against metabolic syndrome, weight gain and extrapyramidal syndrome (EPS) which comprise unmet needs of current market drug together with cognition impairment.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug